Drug Profile
Eprenetapopt - Aprea
Alternative Names: APR-246; PRIMA-1-METLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Aprea
- Developer Aprea; Aprea Therapeutics; H. Lee Moffitt Cancer Center and Research Institute; Jules Bordet Institute; Peter MacCallum Cancer Centre; University of Missouri-Columbia; Victorian Cancer Agency
- Class Antineoplastics; Aza compounds; Ketones; Quinuclidines; Small molecules
- Mechanism of Action Apoptosis stimulants; Thioredoxin reductase inhibitors; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myelodysplastic syndromes
- Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Ovarian cancer
- Phase I/II Chronic lymphocytic leukaemia; CNS cancer; Gastric cancer; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
- Preclinical Endometrial cancer
- No development reported Breast cancer; Haematological malignancies; Lung cancer; Prostate cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Breast-cancer in USA (IV)
- 14 Apr 2023 Preclinical trials in Endometrial cancer (unspecified route)
- 14 Apr 2023 Pharmacodynamics data from preclinical trial in Endometrial cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)